NCT00995709已完成3 期
A 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet¿s Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 118
- 试验地点
- 1
- 主要终点
- Rate of Recurrent Ocular Exacerbations in the Study Eye During 24 Weeks by Treatment
研究概览
简要总结
The purpose of this pivotal trial is to evaluate subcutaneous (SQ) AIN457 as an adjunctive therapy to reduce the rate of exacerbations of posterior uveitis or panuveitis secondary to Behçet's disease during the 24 weeks of study therapy as compared to standard of care alone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with Behçet's disease and with a history of recurrent uveitis in a least one eye.
- •Documented evidence of >2 recurrent exacerbations of either intermediate uveitis, posterior uveitis or panuveitis in the study eye within the past 6 months (this could include the current exacerbation for patients having an acute exacerbation at screening). Exacerbations fulfilling the study inclusion criteria must have one or more of the following recorded in the patients patients medical record for each recurrent exacerbation:
- •>2+ vitreous haze with <2+ anterior chamber cell grade (intermediate or posterior uveitis) or >2+ vitreous haze with >2+ anterior chamber cell grade (panuveitis)
- •presence of retinal infiltrates or vasculitis or hemorrhages
- •documented >10 ETDRS letter or 2 line Snellen decrease in visual acuity attributed to ocular inflammation secondary to the recurrent exacerbation of Behçet's disease.
- •Requirement for either of the following immunosuppressive therapies for at least 3 of the past 6 months for the treatment of or to prevent an exacerbation of ocular inflammation related to Behçet's disease:
- •Prednisone or equivalent >10 mg daily
- •The need for at least >1 periocular injection or >1 intravitreal corticosteroid injection in the study eye within the past 6 months (the last injection must have not been given within 6 weeks of screening)
- •Treatment with cyclosporine, tacrolimus, azathioprine, mycophenolate mofetil, mycophenolic acid or methotrexate either as monotherapy or in combination with or without steroids. (Patients treated at any time with chlorambucil or cyclophosphamide are not eligible for the study.)
- •Patients not meeting the above specified criteria for immunomodulatory therapies are eligible for enrollment if they are intolerant to systemic immunomodulatory therapy as determined by the study investigator.
排除标准
- •Subjects with infectious uveitis, uveitis due to other causes than Behçet's disease, or uveitis of unknown etiology.
- •Less severe (i.e. anterior) uveitis associated with Behçet's disease.
- •Ocular treatments
- •Treatment with intravitreal anti-VEGF agents administered to the study eye within 3 months prior to study screening.
- •Treatment with any injected or implantable corticosteroid releasing device (i.e., flucinolone acetonide implant, Retisert®) in the study eye within the last 3 years.
- •Intraocular surgery or laser photocoagulation in the study eye within the last 6 weeks prior to screening except for a diagnostic vitreous or aqueous tap with a small-gauge needle.
- •Systemic conditions or treatments
- •Treatment with any live or live-attenuated vaccine (including vaccine for varicella-zoster virus or measles) within 2 months prior to screening.
- •Any systemic biologic therapy (e.g. interferon, infliximab, daclizumab, etanercept, or adalimumab) given intravenously or subcutaneously within 3 months prior to screening and no prior treatment with AIN
- •Any prior treatment with systemic alkylating agents (cyclophosphamide, chlorambucil).
- •Other protocol-defined inclusion/exclusion criteria may apply
研究组 & 干预措施
AIN457C 300 mg monthly dosage regimen
Experimental
AIN457 300 mg was administered in 2 subcutaneous (s.c.) injections of 150 mg e
干预措施: AIN457 (Drug)
Placebo
Placebo Comparator
Placebo was administered in 2 s.c. injections every 2 weeks
干预措施: Placebo (Drug)
AIN457C 300 mg every 2 week dosage regimen
Experimental
AIN457 300 mg was administered in 2 subcutaneous (s.c.) injections of 150 mg each. every 2 weeks
干预措施: AIN457 (Drug)
结局指标
主要结局
Rate of Recurrent Ocular Exacerbations in the Study Eye During 24 Weeks by Treatment
时间窗: 24 weeks
Patients number of occurences during a 24 week period.
次要结局
- Change From Baseline for Composite Immunosuppressive Medication Score at Week 24 by Treatment (Full Analysis Set)(24 weeks)
- To Establish the Impact of AIN457 on Quality of Life of Posterior Segment Uveitis Patients Secondary to Behçet's Disease Refractory to Systemic Immunomodulatory Therapy as Measured by National Eye Institute Visual Function Questionaire-25 and Euroqol.(screening, and wk 24 (end of study))
- To Determine the Effect of AIN457 on Macular Edema and Visual Acuity in Patients With Posterior Segment Uveitis Secondary to Behçet's Disease as Determined by Optical Coherence Tomography.(baseline, and wk 24 (end of study))
- To Observe the Effect of AIN457 on the Systemic Non-ocular Manifestations of Behçet's Disease in Patients With Posterior Segment Uveitis Requiring Systemic Immunosuppression as Measured by the Bechet's Disease Current Activity Form.(baseline and wk 24 (end of study))
研究者
研究点 (1)
Loading locations...
相似试验
终止
3 期
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious UveitisNon-infectious UveitisNCT01032915Novartis Pharmaceuticals125
终止
3 期
Safety and Efficacy of AIN457 in Patients With Active Non-infectious UveitisUveitisNCT01095250Novartis Pharmaceuticals30
进行中（未招募）
3 期
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)SclerodermaSystemic SclerosisNCT05925803AstraZeneca314
已完成
3 期
Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff TendinopathyTendinopathyNCT05569174Novartis Pharmaceuticals62
招募中
2 期
A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.AchondroplasiaNCT06732895Ascendis Pharma A/S24